Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - January 2013


2nd Stratified Medicine Conference

22 Jan 2013 - 23 Jan 2013 - Boston, MA, USA



Bookmark and Share


Stratified medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology. As a result, this will enable improved diagnostic tests, more precise diagnoses, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient but also the appropriate dosage to reduce adverse effects.

ExL’s 2nd Stratified Medicine Conference will bring together the industry’s leading stratified and personalized medicine experts to provide you with unique take-home examples, case studies and multiple innovative strategies to implement stratified medicine initiatives within your own organizations.

By attending this conference, you will hear industry-specific case studies and examples including:

Pathways to partnership in therapeutic-diagnostic development

The future of translational research and stratified medicine Innovations in detecting molecular malfunctions impacting cancer research and 
therapy

The role of biomarkers and translational science in the discovery organization

Pursuing stratified medicine: via predictive biomarkers to enhance clinical decision 
making

The regulatory path to approval via stratified medicine Integrating clinical benefits with the economic implications

Examining the importance of pharmacokinetic biomarkers in early clinical 
development decision points

Stratifying patients for clinical trials based on molecular and clinical data

Examining the challenges of companion diagnostics in pharmaceutical development

Exploring models for industry / academia collaboration in stratified medicine

Benefit from industry participation from Pfizer, Merck, MedImmune, Johnson & Johnson, Novartis, Selventa, EMD Serono, Daiichi Sankyo, MIT, and many more personalized and stratified medicine innovators and experts.


 



Further information
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!